Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes

INTRODUCTION: Incretin-based therapies, that is, glucagon-like peptide (GLP)-1 receptor agonists and dipeptidyl peptidase (DPP)-4 inhibitors, are relatively novel antihyperglycaemic drugs that are frequently used in type 2 diabetes management. Apart from glucose-lowering, these agents exhibit pleiot...

Descripción completa

Detalles Bibliográficos
Autores principales: Smits, Mark M, Tonneijck, Lennart, Muskiet, Marcel H A, Hoekstra, Trynke, Kramer, Mark H H, Pieters, Indra C, Cahen, Djuna L, Diamant, Michaela, van Raalte, Daniël H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Diabetes and Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4654309/
https://www.ncbi.nlm.nih.gov/pubmed/26586327
http://dx.doi.org/10.1136/bmjopen-2015-009579

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4654309/
https://www.ncbi.nlm.nih.gov/pubmed/26586327
http://dx.doi.org/10.1136/bmjopen-2015-009579

Ejemplares similares